Zai lab and argenx announce approval of efgartigimod alfa injection (subcutaneous injection) for generalized myasthenia gravis in china

Shanghai & cambridge, mass.--(business wire)--zai lab limited (nasdaq: zlab; hkex: 9688) and argenx (euronext & nasdaq: argx) today announced that china's national medical products administration (nmpa) approved the biologics license application (bla) for efgartigimod alfa injection (subcutaneous injection) (efgartigimod sc), 1,000mg (5.6ml)/vial indicated as an add on to standard therapy for the treatment of adult patients with generalized myasthenia gravis (gmg) who are anti-acetylcholine.
ARGX Ratings Summary
ARGX Quant Ranking